HAIP Chemo Offers OS Advantage in Advanced Intrahepatic Cholangiocarcinoma
SAN FRANCISCO — Hepatic arterial infusion pump (HAIP) chemotherapy with floxuridine significantly improved overall survival (OS) in patients with advanced intrahepatic cholangiocarcinoma (iCCA), according to results from a phase II study. Patients treated with HAIP chemotherapy combined with systemic chemotherapy achieved a 1-year OS of 80% compared with 47% in the historical cohort treated with […]